Article: NICE Backs Xolair(R)-Delta for Severe, Persistent Allergic Asthma.

FRIMLEY, England, August 31 /PRNewswire/ --

- Clinicians Welcome Drug Watchdog's Decision to Grant NHS Patients Access to Xolair(R) (Omalizumab) for Severe, Persistent Allergic Asthma.

Novartis today welcomes the decision made by the National Institute for Health and Clinical Excellence (NICE) to recommend the use of Xolair(R) (omalizumab) in adolescents (12 years of age and above) and adults with severe, persistent allergic asthma(1). Evidence shows that, when used as add-on treatment, Xolair can significantly improve symptom contro(l2) and quality of life in those patients in whom best current management has failed.

Xolair is the first drug shown to stabilise ...

Related newspaper, magazine, and journal articles:

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!